Antimicrobial susceptibility of Salmonella enterica serovars in a tertiary care hospital in Southern India

Indian Journal of Medical Research

Volumn 137, Issue 4, 2013, Pages 800-802

  Choudhary, Ashwini ^a   Gopalakrishnan, Ram ^a   Senthur Nambi, P ^a   Ramasubramanian, V ^a   Abdul Ghafur, K ^a   Thirunarayan, M A ^b  

^a Apollo Hospitals   (India)

^b APOLLO HOSPITALS   (India)

Author keywords

Antimicrobial susceptibility; Azithromycin; Ciprofloxacin; Co trimoxazole; Salmonella; Typhoid

Indexed keywords

AZITHROMYCIN; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; NALIDIXIC ACID;

ANTIBIOTIC SENSITIVITY; ARTICLE; BLOOD CULTURE; BONE MARROW TOXICITY; DISK DIFFUSION; EPSILOMETER TEST; HUMAN; INDIA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SALMONELLA ENTERICA; TERTIARY HEALTH CARE; TYPHOID FEVER;

AMPICILLIN; CHLORAMPHENICOL; CIPROFLOXACIN; DISK DIFFUSION ANTIMICROBIAL TESTS; DRUG RESISTANCE, BACTERIAL; HUMANS; INDIA; MICROBIAL SENSITIVITY TESTS; NALIDIXIC ACID; SALMONELLA PARATYPHI A; SALMONELLA TYPHI; TERTIARY HEALTHCARE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; TYPHOID FEVER;

EID: 84877741851     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Madhulika U, Harish BN, Parija SC. Current pattern in antimicrobial susceptibility of Salmonella Typhi isolates in Pondicherry. Indian J Med Res 2004; 120: 111-4.
2. Brown JC, Shanahan PM, Jesudason MV, Thomson CJ, Amyes SG. Mutations responsible for reduced susceptibility to 4-quinolones in clinical isolates of multi-resistant Salmonella Typhi in India. J Antimicrob Chemother 1996; 37: 891-900.
3. Effa EE, Bukirwa H. Azithromycin for treating uncomplicated typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst Rev 2008; (4): CD006083.
4. Menezes GA, Harish BN, Khan MA, Goessens WH, Hays JP. Antimicrobial resistance trends in blood culture positive Salmonella Typhi isolates from Pondicherry, India, 2005-2009. Clin Microbiol Infect 2012; 18: 239-45.
5. Harish BN, Menezes GA. Preserving efficacy of chloramphenicol against typhoid fever in a tertiary care hospital, India. Reg Health Forum 2011; 15: 92-6.
6. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial disk susceptibility tests. Approved Standard-9th ed., CLSI Document M2-A9. Wayne, PA: CLSI; 2006.
7. European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters Version 1.3, 2011. Vaxjo, Sweden. Available from: http://www.eucast.org/fileadmin/src/media/pdfs/EUCAST-files/Disk-test-documents/EUCAST_breakpoints_vl.3.pdf.pdf.
8. Manchanda V, Bhalla P, Sethi M, Sharma VK. Treatment of enteric fever in children on the basis of current trends of antimicrobial susceptibility of Salmonella enterica serovar typhi and paratyphi A. Indian J Med Microbiol 2006; 24: 101-6.
9. Chandel DS, Chaudhry R, Dhawan B, Pandey A, Dey AB. Drug-resistant Salmonella enterica serotype paratyphi A in India. Emerg Infect Dis 2000; 6: 420-1.
10. Nath G, Tikoo A, Manocha H, Tripathi AK, Gulati AK. Drug resistance in Salmonella Typhi in north India with special reference to ciprofloxacin. J Antimicrob Chemother 2003; 46: 145-53.
11. Mandal S, Mandal MD, Pal VK. Nalidaxic acid resistance predicting reduced ciprofloxacin susceptibility of Salmonella enterica seroval typhi. Asian Pacific J Trop Dis 2012; 2 (Suppl 2): S585-7.
12. Crump JA, Barett TJ, Nelson JI, Angulo FJ. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae. Clin Infect Dis 2003; 37: 75-81.
13. Harish BN, Menezes GA. Antimicrobial resistance in typhoidal salmonellae. Indian J Med Microbiol 2011; 29: 223-9.
14. Parry CM, Thuy CT, Dongol S, Karkey A, Vinh H, Chinh NT, et al. Suitable disk antimicrobial susceptibility breakpoints defining Salmonella enterica serovar Typhi isolates with reduced susceptibility to fluoroquinolones. Antimicrob Agents Chemother 2010; 54: 5201-8.
15. Ray P, Sharma J, Marak RSK, Garg RK. Predictive efficacy of nalidixic acid resistance as a marker of fluoroquinolone resistance in Salmonella enterica var Typhi. Indian J Med Res 2006; 124: 105-8.
16. Mirza SH, Beeching NJ, Hart CA. Multi-drug resistant typhoid: a global problem. J Med Microbiol 1996; 44: 317-9.
17. Nagshetty K, Channappa ST, Gaddad SM. Antimicrobial susceptibility of Salmonella Typhi in India. J Infect Dev Ctries 2010; 4: 70-3.
18. Parry CM. The treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever in Vietnam. Trans R Soc Trop Med Hyg 2004; 98: 413-22.
19. Tankhiwale SS, Agrawal G, Jalgaonkar SV. A preliminary report on current antibiogram of Salmonella enterica serotype Typhi in Nagpur. Indian J Med Microbiol 2003; 21: 292.
20. Pfeifer Y, Matten J, Rabsch W. Salmonella enterica Serovar Typhi with CTX-M beta-lactamase, Germany. Emerg Infect Dis 2009; 15: 1533-5.
21. Molloy A, Nair S, Cooke FJ, Wain J, Farrington M, Lehner PJ, et al. First report of Salmonella enterica serotype paratyphi A arzithromycin resistance leading to treatment failure. J Clin Microbiol 2010; 48: 4655-7.
22. Gokul BN, Menezes GA, Harish BN. Acc-1 β-lactamase-producing Salmonella enterica serovar Typhi, India. Emerg Infect Dis 2010; 16: 1170-1.
23. Jog S, Soman R, Singhal T, Rodrigues C, Mehta A, Dastur FD. Enteric fever in Mumbai-clinical profile, sensitivity patterns and response to antimicrobials. J Assoc Physicians India 2008; 56: 237-40.